SCHEMBL990670

SCHEMBL990670

Cc1cnc(N2CCN(C)CC2)cc1C1=C(c2c[nH]c3ccccc23)C(=O)NC1=O

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCH P24723 18/20 0.71
PRKCD Q05655 18/20 0.71
PRKCQ Q04759 17/20 0.71
PRKCA P17252 17/20 0.71
PRKCE Q02156 16/20 0.71
PRKCB P05771 16/20 0.71
PRKCG P05129 3/20 0.60
PRKCZ Q05513 3/20 0.60
CAMK2D Q13557 3/20 0.60
CDK2 P24941 3/20 0.60
CAMK2B Q13554 2/20 0.60
CAMK2G Q13555 2/20 0.60
CAMK2A Q9UQM7 2/20 0.60
JAK3 P52333 2/20 0.60
PRKD3 O94806 2/20 0.60
ABL1 P00519 2/20 0.60
CDK1 P06493 2/20 0.60
PIM1 P11309 2/20 0.60
PRKCI P41743 2/20 0.60
PDPK1 O15530 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL992515 0.89 PRKCH (0.69) PRKCHPRKCDPRKCQPRKCAPRKCE
SCHEMBL991233 0.88 PRKCH (0.65) PRKCHPRKCDPRKCQPRKCAPRKCE
SCHEMBL990658 0.87 PRKCH (0.62) PRKCHPRKCDPRKCQPRKCAPRKCE
SCHEMBL990717 0.87 PRKCA (0.66) PRKCHPRKCDPRKCQPRKCAPRKCE
SCHEMBL4377883 0.83 PRKCH (1.00) PRKCHPRKCDPRKCQPRKCAPRKCE
SCHEMBL4380148 0.81 PRKCH (1.00) PRKCHPRKCDPRKCQPRKCAPRKCE
SCHEMBL990652 0.79 PRKCA (0.60) PRKCHPRKCDPRKCQPRKCAPRKCE
SCHEMBL4077139 0.78 PRKCH (0.73) PRKCHPRKCDPRKCQPRKCAPRKCE
SCHEMBL991340 0.78 PRKCH (0.76) PRKCHPRKCDPRKCQPRKCAPRKCE
SCHEMBL989017 0.77 PRKCA (0.66) PRKCHPRKCDPRKCQPRKCAPRKCE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2270001-A1 Indolylmaleimide derivatives as PKC inhibitors Novartis AG (CH) 2011-01-05 EP claimed
US-7648989-B2 Indolylmaleimide derivatives as PKC inhibitors NOVARTIS AG (CH) 2010-01-19 US claimed
US-20080242675-A1 Indolylmaleimide Derivatives as Pkc Inhibitors NOVARTIS AG (CH) 2008-10-02 US claimed
JP-2007518731-A 2007-07-12 JP claimed
EP-1745037-A1 INDOLYLMALEIMIDE DERIVATIVES AS PKC INHIBITORS Novartis AG (CH) 2007-01-24 EP claimed
WO-2005068455-A1 INDOLYLMALEIMDE DERIVATIVES AS PKC INHIBITORS NOVARTIS AG (CH) 2005-07-28 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242675-A1 Indolylmaleimide Derivatives as Pkc Inhibitors PRKCE, PRKCH, PRKCI PRKCH 2/4885PRKCD 6/4885PRKCQ 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.